Related Experiment Video
Updated: Apr 30, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Adverse Prognostic Significance of Activation-Induced Cytidine Deaminase in Diffuse Large B-Cell Lymphoma Patients
Mardiah Suci Hardianti1, Nungki Anggorowati2, Syahru Agung Setiawan1
1Division of Hematology and Medical-Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Background:
A number of studies have demonstrated the important role of activation-induced cytidine deaminase (AID) in the pathogenesis of diffuse large B-cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.
Aims:
This study conducted a comprehensive analysis of the association between AID expression and clinical outcomes in 70 Indonesian patients with DLBCL treated with a standard CHOP ± rituximab regimen.
Methods And Results:
Immunostaining results showed that AID was expressed in 35.7% of DLBCL samples. Multivariate analysis indicated that positive AID expression was associated with shorter overall survival (OS) specifically among patients receiving a rituximab-containing regimen, with a hazard ratio of 10.39 (95% CI: 1.93-55.96; p = 0.006).
Conclusion:
The significant prognostic value of AID in the DLBCL subgroup treated with rituximab-but not in the general DLBCL population or in those not receiving rituximab-underscores the potential relevance of AID expression in DLBCL management and treatment decisions.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
